Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
gptkb:Cadence_Pharmaceuticals
gptkb:Questcor_Pharmaceuticals |
| gptkbp:CEO |
gptkb:Siggi_Olafsson
|
| gptkbp:countryOfOrigin |
gptkb:United_States
|
| gptkbp:filedForBankruptcy |
2020
2023 |
| gptkbp:founded |
1867
|
| gptkbp:founder |
gptkb:Gustav_Mallinckrodt
|
| gptkbp:headquartersLocation |
gptkb:St._Louis,_Missouri,_United_States
gptkb:Staines-upon-Thames,_United_Kingdom |
| https://www.w3.org/2000/01/rdf-schema#label |
Mallinckrodt
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:involvedIn |
opioid litigation
|
| gptkbp:notableProduct |
gptkb:Acthar_Gel
gptkb:INOMAX gptkb:Ofirmev |
| gptkbp:numberOfEmployees |
~3,400 (2023)
|
| gptkbp:products |
generic drugs
contrast media specialty pharmaceuticals |
| gptkbp:spinOff |
gptkb:Covidien
|
| gptkbp:tradedOn |
gptkb:NYSE:_MNK
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.mallinckrodt.com/
|
| gptkbp:bfsParent |
gptkb:Tyco_Healthcare
|
| gptkbp:bfsLayer |
6
|